Prevalence of diseases of inflammaging. The prevalence of diseases of inflammaging in months −60 through −6 before diagnosis or at the pseudodiagnosis date was determined for patients with MDS/CMML, invasive solid tumor, or a representative Medicare population. Forest plots show ORs for prevalent diseases of inflammaging. (A) MDS/CMML vs representative Medicare by disease group. (B) MDS/CMML vs representative Medicare by individual diagnosis. (C) MDS/CMML vs solid tumor by disease group. Number of patients, prevalence (%), and OR (95%CI) are presented at the right of the forest plot. (D) MDS/CMML vs solid malignancy by individual diagnosis. Cardiovascular disease includes atherosclerotic heart disease, myocardial infarction (MI), cerebrovascular accident (CVA), and cardiomyopathy (heart failure); pulmonary disease includes chronic obstructive pulmonary disease (COPD), asthma, and chronic bronchitis; bone and joint diseases include a combination of osteopenia, osteoporosis, osteoarthritis, rheumatoid arthritis (RA), and gout; metabolic diseases include type 2 diabetes mellitus (T2DM), insulin resistance, fatty liver, and chronic kidney disease (CKD); and neurologic diseases include Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), age-related macular degeneration, and non-Alzheimer dementias (other dementias). Numerical values for the ORs and 95% CIs for individual diagnoses are provided in supplemental Table 1.